Copyright
©The Author(s) 2024.
World J Hepatol. Mar 27, 2024; 16(3): 465-476
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.465
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.465
Ref. | Ateş et al[8] | Jin et al[9] | Gong et al[10] | Liu et al[11] | Zhu et al[12] | Kim et al[13] | Cho et al[14] | Lee et al[15] | Chen et al[16] | Li et al[17] | Liang et al[18] | |
Year | 2011 | 2012 | 2015 | 2015 | 2016 | 2019 | 2019 | 2019 | 2020 | 2020 | 2021 | |
Location | Turkey | China | China | China | China | Korea | Korea | Korea | China | United States | China | |
Study | Prospective study | Prospective study | Prospective study | Prospective study | Retrospective study | Retrospective study | Retrospective study | Retrospective study | Retrospective study | Retrospective study | Prospective study | |
Journal | World J Gastroenterol | PLoS One | Transplant Proc | J Interferon Cytokine Res | Drug Des Devel Ther | Clin Mol Hepatol | J Clin Gastroenterol | Clin Mol Hepatol | BMC Gastroenterol | Liver Int | Gastroenterol Res Pract | |
Therapy regimen | PEG-IFN | Nucleos(t)ide analogues | PEG-IFN | Nucleos(t)ide analogues | Nucleos(t)ide analogues | Nucleos(t)ide analogues | Nucleos(t)ide analogues | Nucleos(t)ide analogues | Nucleos(t)ide analogues | Nucleos(t)ide analogues | PEG-IFN | |
Male | CHB with NAFLD | 95 | 32 | 20 | 23 | 42 | 91 | 171 | 50 | 43 | 126 | 95 |
CHB | 82 | 85 | 38 | 12 | 41 | 119 | 333 | 146 | 43 | 211 | 82 | |
Famale | CHB with NAFLD | 12 | 33 | 11 | 17 | 19 | 69 | 89 | 20 | 13 | 61 | 12 |
CHB | 3 | 63 | 20 | 8 | 23 | 69 | 233 | 105 | 13 | 157 | 37 | |
Age | CHB with NAFLD | 50.5 ± 8.7 | 39.56 ± 11.87 | 30.3 ± 7.4 | 37.70 ± 7.90 | 39.26 ± 10.39 | 51.0 (42.0-56.3) | 52.0 ± 9.4 | 45 (36–51) | 39 (31-34) | 47.7 ± 12.5 | 20.87 ± 1.96 |
CHB | 35.2 ± 8.9 | 39.55 ± 7.83 | 25.1 ± 7.8 | 37.35 ± 8.49 | 39.61 ± 10.87 | 51.0 (43.3-57.0) | 54.0 ± 8.8 | 41 (32–48) | 38.5 (31–44) | 45.5 ± 14.6 | 29.50 ± 5.47 | |
BMI | CHB with NAFLD | 32.9 ± 3.1 | 26.35 ± 4.19 | 25.3 ± 2.1 | 28.16 ± 1.43 | 26.29 ± 3.99 | 24.7 (22.3-26.7 | 24.5 ± 3.5 | NA | 25.0 ± 3.0 | 25.4 ± 4.3 | NA |
CHB | 25.7 ± 3.3 | 24.26 ± 3.41 | 22.5 ± 2.9 | 22.06 ± 1.02 | 22.50 ± 2.85 | 22.5 (20.4-24.4) | 23.8 ± 3.2 | NA | 23.0 ± 3.0 | 23.8 ± 4.0 | 20.87 ± 1.96 | |
ALT | CHB with NAFLD | 128.3 ± 18.9 | 143.3 ± 82.1 | 171.68 ± 46.23 | 227.70 ± 121.14 | 179.87 ± 78.50 | 56 (38-94) | NA | 71 (32–114) | 99 (68-154) | 60 (15 - 1525) | NA |
CHB | 139.2 ± 52.5 | 157.1 ± 108.3 | 159.18 ± 45.12 | 229.95 ± 137.36 | 187.95 ± 79.88 | 56 (34-90) | NA | 94 (45–171) | 124 (79–216) | 50 (14 - 1079) | 257.39 ± 175.17 | |
AST | CHB with NAFLD | 90.7 ± 34.8 | 70.2 ± 33.7 | 59.66 ± 13.81 | 183.23 ± 103.70 | NA | NA | NA | 53 (36–86) | 61 (38-84) | 37 (13 - 1465) | NA |
CHB | 107.0 ± 40.3 | 93.5 ± 72.3 | 56.63 ± 13.13 | 167.60 ± 85.07 | NA | NA | NA | 85 (51–153) | 72 (45–137) | 35 (12 - 863) | 126.72 ± 79.55 | |
GGT | CHB with NAFLD | 49.8 ± 29.8 | 95.2 ± 73.2 | 42.92 ± 14.83 | 98.75 – 19.90 | NA | NA | NA | NA | NA | NA | NA |
CHB | 50.0 ± 44.0 | 77.2 ± 89.7 | 46.05 ± 11.36 | 51.41 – 5.46 | NA | NA | NA | NA | NA | NA | NA | |
TB | CHB with NAFLD | NA | NA | NA | NA | NA | 0.8 (0.7-1.1) | 1.0 ± 0.4 | NA | 0.8 (0.6-1.0) | 1.3 ± 3.0 | NA |
CHB | NA | NA | NA | NA | NA | 0.9 (0.7-1.2) | 1.1 ± 0.4 | NA | 1.0 (0.7–1.2) | 1.3 ± 2.7 | NA | |
ALB | CHB with NAFLD | NA | NA | NA | NA | NA | 4.2 (4.0-4.4) | 4.18 ± 0.3 | 4.2 (3.8–4.4) | NA | 4.0 ± 0.6 | NA |
CHB | NA | NA | NA | NA | NA | 4.2 (3.9-4.4) | 4.25 ± 0.4 | 4.0 (3.7–4.3) | NA | 3.9 ± 0.6 | NA | |
TC | CHB with NAFLD | 192.2 ± 28.0 | 84.6 ± 14.4 | 80.28 ± 7.92 | 115.02 ± 9 | 68.04 ± 1.26 | 178 (151-204) | NA | 176 (155–203) | NA | 181 ± 40 | NA |
CHB | 178.0 ± 27.4 | 81.0 ± 14.4 | 78.66 ± 5.76 | 81.18 ± 8.1 | 66.96 ± 17.46 | 170 (151-190) | NA | 159 (137–179) | NA | 177 ± 41 | 0.56 ± 0.45 | |
TG | CHB with NAFLD | 188.3 ± 52.0 | 34.2 ± 14.4 | 27.54 ± 6.84 | 48.06 ± 10.98 | 32.4 ± 16.2 | NA | NA | 103 (81–137) | NA | 189 ± 153 | NA |
CHB | 114.2 ± 44.2 | 21.6 ± 9 | 19.98 ± 7.02 | 25.92 ± 2.88 | 23.94 ± 11.52 | NA | NA | 80 (63–109) | NA | 86 ± 42 | 4.68 ± 0.80 | |
HDL | CHB with NAFLD | NA | NA | NA | NA | 15.48 ± 6.12 | NA | NA | 44.4 (35.4–54.4) | NA | 40 ± 9 | NA |
CHB | NA | NA | NA | NA | 19.26 ± 6.3 | NA | NA | 48.3 (39.4–59.4) | NA | 58 ± 19 | NA | |
LDL | CHB with NAFLD | NA | NA | NA | NA | 41.58 ± 12.96 | 113 (93-129) | NA | 105 (87–129) | NA | 111 ± 37 | NA |
CHB | NA | NA | NA | NA | 38.88 ± 12.24 | 101 (80-126) | NA | 90 (75–108) | NA | 106 ± 32 | NA | |
Glucose | CHB with NAFLD | 102.7 ± 27.7 | 4.8 ± 0.6 | 5.46 ± 1.37 | NA | 5.11 ± 0.85 | 96.0 (89.3-107.0) | NA | 103 (92–117) | NA | 115 ± 37 | NA |
CHB | 96.7 ± 19.0 | 4.5 ± 0.5 | 5.07 ± 0.92 | NA | 4.89 ± 0.80 | 9 4.0 (87.3-102) | NA | 98 (90–108) | NA | 105 ± 26 | NA | |
Quality scores | 6 | 7 | 7 | 6 | 6 | 7 | 8 | 6 | 7 | 6 | 6 |
- Citation: Liu SY, Wang D, Liu J, Yang LP, Chen GY. Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis. World J Hepatol 2024; 16(3): 465-476
- URL: https://www.wjgnet.com/1948-5182/full/v16/i3/465.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i3.465